VIRUS INACTIVATION OF HUMAN RED CELLS FOR TRANSFUSION

本提案的长期目标是开发一种实用的方法来灭活污染输血用血液的病毒。 全世界每年输注超过3000万单位的红细胞，估计市场超过30亿美元。 有效的病毒净化程序将解决巨大的未满足的需求，并代表着重大的市场机会。 我们在存在红细胞的情况下获得了初步结果，其证明了对许多不同包膜和无包膜病毒的稳健杀伤，包括人B19细小病毒和丙型肝炎病毒的模型病毒。 这种杀灭是使用一类新型病毒灭活剂INACTINE（TM）化合物实现的，该化合物对核酸的选择性高于蛋白质或其他生物分子。 我们建议进一步研究和优化在红细胞存在下的病毒杀伤。 然后，我们将研究INACTINE（TM）处理在这些优化条件下对红细胞生理学的影响。 这些结果将为一个扩大的项目奠定基础，以开发一种在血库环境中处理红细胞的有效方法。拟议的商业应用：尽管由于广泛的供体筛选和测试，美国的血液供应被认为是相当安全的，但仍然非常需要安全、有效的病毒灭活程序。 新的血液传播病毒正在被发现，已知病毒感染的风险是34，000单位血液中的l。 因此，INACTINE（TM）病毒灭活技术在血库行业中具有很大的市场机会。

The long-term objective of this proposal is to develop a practical method for inactivating the viruses that contaminate blood for transfusion. Over 30 million units of red blood cells are transfused annually worldwide, representing an estimated market of over 3 billion dollars. An effective virus decontamination procedure would address an enormous unmet need and represent a significant market opportunity. We obtained preliminary results in the presence of red blood cells that demonstrated robust killing of a number of different enveloped and non-enveloped viruses, including model viruses for human Bl9 parvovirus and hepatitis C virus. This killing was achieved using a novel class of viral inactivating agents, INACTINE (TM) compounds, which are highly selective for nucleic acids over proteins or other biomolecules. we propose to further study and optimize the virus killing in the presence of red blood cells. Then we will study the effect of INACTINE(TM) treatment on red blood cell physiology under these optimized conditions. These results will set the stage for an expanded program to develop an effective method for treating red blood cells in a blood bank setting. PROPOSED COMMERCIAL APPLICATIONS: Although the US blood supply is considered quite safe as a result of extensive donor screening and testing, there is a still great need for safe, effective virus inactivation procedure(s). New blood-borne viruses are being discovered and the risk of infection from known viruses is l in 34,000 units of blood. Therefore, there is a large market opportunity for the INACTINE(TM) virus inactivation technology in the blood banking industry.